Amalgamated Financial’s Edwards Lifesciences EW Stock Holding History

Amalgamated Financial’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$20.6M	Buy	+175,123	New	+$19.6M	0.16%	96

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amalgamated Financial's EW Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Edwards Lifesciences (EW) in Q1 2022: 175,123 shares worth $20.6M. The stake represents 0.16% of the portfolio and ranks #96 among its holdings.

1,315 funds tracked by Wall St. Rank hold EW as of Q1 2022.

Amalgamated Financial held 175,123 shares of Edwards Lifesciences worth $20.6M as of Q1 2022.
Edwards Lifesciences was a new Amalgamated Financial position in Q1 2022.
Edwards Lifesciences made up 0.16% of Amalgamated Financial's portfolio in Q1 2022, its #96 holding.
1,315 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.